BlogsTag: IO Insights
Why SIO? Why now?
Blog: Clinic Notes | Posted By: Michael C. Soulen | Released: February 16, 2017, 7:15 pm
Optimal patient care is no longer the province of solitary specialists; rather it is provided by multidisciplinary care teams. This has lead to the genesis of diseased-centered subspecialty societies
Abstract Submissions Skyrocket for WCIO 2014
Blog: Clinic Notes | Posted By: Michael C. Soulen | Released: January 25, 2014, 1:25 pm
I just finished reviewing my assigned batch of the hundreds of abstracts submitted to WCIO for our 10th annual scientific meeting in New York May 11-14, and what an exciting bunch they were! The amount of innovation in the field of IO is astounding.
New Years Resolutions
Blog: Clinic Notes | Posted By: Michael C. Soulen | Released: January 12, 2014, 6:57 am
The start of a new year is a great time to look back and forwards. WCIO made the leap from a freestanding annual scientific congress to become the world community for IO in 2010. We quickly launched IO Central, the global on-line open-membership forum for IO...
Survival with up to 10-year Follow-up after Combination Therapy of Chemoembolization and Radiofreque
Blog: IO Insights | Posted By: Erica Lucca | Released: June 10, 2013, 6:46 am
Researchers in a new study sought to report 10-year outcomes of treating hepatocellular carcinomas (HCCs) by combination therapy of chemoembolization and radiofrequency (RF) ablation. Combination therapy was administered in 277 patients with 382 treatment-naïve HCCs. Therapeutic effects, safety, sur
RFA and Immunostimulant OK-432: Combination Therapy Enhances Systemic Antitumor Immunity for Treatme
Blog: IO Insights | Posted By: Erica Lucca | Released: June 10, 2013, 6:45 am
Researchers in Japan conducted a study to evaluate whether antitumor immunity is enhanced systemically by combining radiofrequency ablation (RFA) and local injection of an immunostimulant, OK-432. Rabbits were inoculated with VX2 tumors in the lung and the auricle were randomized into four groups of